Drugs / Krestin
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00546130 | Nov 2007 → Sep 2011 | small cell lung carcinoma | University of Toyama | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00503321 | Oct 2006 → Aug 2009 | gastric cancer | Eastern Network of Cancer Immunological Therapy, Japan | Terminated | No outcome recorded Stop: Enrollment |
| Phase 34 trials | ||||||
| Phase 3 | NCT00687843 | Jun 2008 → Mar 2016 | gastric cancer | Tokyo Metropolitan Oncology Group | Unknown | No outcome recorded |
| Phase 3 | NCT00385970 | Mar 2006 → Apr 2015 | colorectal cancer | Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group | Unknown | No outcome recorded |
| Phase 3 | NCT00209742 | Apr 2005 → Dec 2012 | colorectal cancer | Hokkaido Gastrointestinal Cancer Study Group | Unknown | No outcome recorded |
| Phase 3 | NCT00216034 | Mar 2005 → Feb 2016 | gastric cancer | Hokuriku-Kinki Immunochemotherapy Study Group | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Krestin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00216034 ↗ |
| Known as | Krestin: PSK | “Krestin: PSK” NCT00546130 ↗ |
| Known as | PSK | “Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK)” NCT00503321 ↗1“Krestin (PSK)” NCT00385970 ↗ |
| Route | Oral | “P.O. everyday” NCT00209742 ↗ |